Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of "Hold" from Brokerages

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) has been given an average rating of "Hold" by the five ratings firms that are presently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $7.00.

Several research analysts have commented on the company. TD Securities downgraded Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 1st. TD Cowen downgraded Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, April 1st. HC Wainwright upgraded Milestone Pharmaceuticals to a "buy" rating and set a $5.00 target price for the company in a research note on Thursday, June 5th. Finally, Cowen downgraded Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 1st.

Milestone Pharmaceuticals Trading Down 1.8%

Shares of MIST opened at $1.65 on Monday. The business has a 50-day moving average of $1.28 and a 200 day moving average of $1.68. Milestone Pharmaceuticals has a fifty-two week low of $0.63 and a fifty-two week high of $2.75. The firm has a market cap of $88.22 million, a P/E ratio of -2.04 and a beta of 0.92. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.12). As a group, research analysts forecast that Milestone Pharmaceuticals will post -0.62 EPS for the current year.

Institutional Trading of Milestone Pharmaceuticals

A number of large investors have recently modified their holdings of MIST. Propel Bio Management LLC bought a new stake in shares of Milestone Pharmaceuticals during the 1st quarter valued at about $1,161,000. Toronto Dominion Bank bought a new stake in shares of Milestone Pharmaceuticals during the 4th quarter valued at about $1,770,000. Boxer Capital Management LLC bought a new stake in shares of Milestone Pharmaceuticals during the 4th quarter valued at about $729,000. Walleye Capital LLC bought a new stake in shares of Milestone Pharmaceuticals during the 1st quarter valued at about $74,000. Finally, Virtu Financial LLC bought a new stake in shares of Milestone Pharmaceuticals during the 4th quarter valued at about $170,000. Institutional investors own 86.18% of the company's stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.